Bandaram Pharma Packtech Ltd (524602)
🎯 Key Takeaways
- Bandaram Pharma Packtech Ltd appears to be in a consolidation and stabilization phase, with minimal revenue growth and volatile profitability over the past year. The company operates in niche segments of pharmaceutical packaging and contract manufacturing, but recent quarters show flat revenue and inconsistent earnings.
- Revenue declined 8.8% QoQ to ₹24 in Q1FY27.
- ⚠️ Persistent revenue volatility with no clear upward trend despite margin improvements, signaling fragile demand or pricing pressure.
📖 The Story
Bandaram Pharma Packtech Ltd appears to be in a consolidation and stabilization phase, with minimal revenue growth and volatile profitability over the past year. The company operates in niche segments of pharmaceutical packaging and contract manufacturing, but recent quarters show flat revenue and inconsistent earnings. Despite a high P/E of 62, ROCE remains modest at 10.4%, suggesting limited capital efficiency. Management has not signaled aggressive expansion, and the business remains small with a market cap of ₹33 crore.
📰 What's Happening
In the latest quarter (Jun 2026), the company reported revenue of ₹24 crore with an operating profit of ₹1 crore and an OPM of 5.6%, up from ₹14 crore revenue and 2.3% OPM in Sep 2025. This improvement in margins appears driven by operational efficiency rather than volume growth. The March 2026 balance sheet shows total assets of ₹76 crore, up from ₹40 crore a year ago, indicating capital investment. However, no major new contracts or capacity expansions were disclosed in recent filings, and management has not announced any strategic pivots or new product lines.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 8 | 14 | 15 | 26 | 24 |
| Operating Profit | 1 | 0 | 1 | 1 | 1 |
| OPM % | 6.2% | 2.3% | 5.8% | 2.2% | 5.6% |
| Net Profit | 0 | 0 | 0 | 0 | 1 |
| EPS | ₹0.02 | ₹0.03 | ₹0.11 | ₹0.05 | ₹0.11 |
Revenue has fluctuated significantly over the past year, peaking at ₹26 crore in Mar 2026 before declining to ₹14 crore in Sep 2025, but showed a rebound to ₹24 crore in Jun 2026. Profitability remains erratic, with net profit of ₹1 crore in Jun 2026 and ₹1 crore in Dec 2025, but zero profit in Mar 2026 and Sep 2025. The inconsistent NP and EPS trends suggest operational volatility, though OPM improved to 5.6% in the latest quarter from as low as 2.2% in Mar 2026, indicating some margin recovery. However, the lack of sustained growth in revenue or earnings raises concerns about scalability.
🔮 Management Outlook & What's Next
Management has not provided forward guidance in the latest filings, and there is no explicit commentary on future revenue targets, margin improvement, or capacity plans in the recent quarterly results or annual report extracts. The company’s disclosures remain focused on operational performance without strategic outlook. Previous filings show no major acquisitions or divestments, and management continues to emphasize cost control without articulating a clear growth narrative. Without stated objectives for scaling or diversification, the strategic direction remains ambiguous.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 18 |
| Reserves | 1 | 1 | 1 | 9 |
| Borrowings | 15 | 17 | 22 | 24 |
| Total Liabilities | 34 | 39 | 40 | 76 |
| Fixed Assets | 4 | 4 | 4 | 9 |
| Investments | 1 | 1 | 1 | 0 |
| Total Assets | 34 | 39 | 40 | 76 |
The balance sheet shows a steady increase in total assets from ₹39 crore in Mar 2025 to ₹76 crore in Mar 2026, suggesting active capital deployment. However, this growth is accompanied by a rise in borrowings from ₹17 crore to ₹24 crore, while equity only improved marginally from ₹12 crore to ₹18 crore. This indicates that asset growth is largely debt-financed, raising concerns about leverage sustainability. Reserves remain minimal, and the equity base has not expanded significantly through retained earnings, implying limited reinvestment from profits.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -5 |
| Investing | -0 |
| Financing | +5 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 62.6% | 62.7% | 62.7% |
| FII | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% |
| Public | 36.3% | 36.2% | 36.2% |
| # Shareholders | 5,095 | 5,078 | 5,103 |
Promoter holding remains stable at 62.66% over the last four quarters, with no signs of dilution or stake sales. Institutional ownership (FII/DII) remains negligible at 0%, and the number of public shareholders has slightly increased from 5,078 to 5,103, suggesting minor retail interest. There are no indications of activist activity or significant investor exits. The lack of institutional interest may reflect skepticism about the company’s growth prospects or return potential.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | 22.9% | 0.60 |
| MANIPALHOS | 1.00 L Cr | — | — | — | 1.25 |
| MAXHEALTH | 99,174 | 68.0 | 14.4% | 13.6% | 0.27 |
| FORTIS | 68,550 | 65.4 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 65,881 | 122.3 | 17.2% | 11.9% | 0.21 |
| MEDANTA | 39,854 | 71.6 | 21.9% | 16.3% | 0.10 |
| NH | 38,979 | 47.5 | 13.7% | 18.0% | 1.07 |
| LALPATHLAB | 32,521 | 46.8 | 29.6% | 21.8% | 0.00 |
| KIMS | 31,685 | 147.9 | 9.7% | 8.7% | 1.44 |
| POLYMED | 17,871 | 56.7 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent revenue volatility with no clear upward trend despite margin improvements, signaling fragile demand or pricing pressure. 2. High leverage relative to equity, with borrowings rising faster than asset growth, increasing financial risk. 3. Absence of forward guidance or strategic clarity from management, leaving investors without visibility into growth drivers. 4. Low ROE and ROCE despite high valuation multiples, suggesting market may be pricing in unmet expectations without fundamental justification.
🧠 Analyst's Read
Bandaram Pharma Packtech is a micro-cap company with inconsistent financial performance, rising leverage, and no clear growth trajectory. Investors should monitor quarterly revenue trends and any future disclosures on order book, capacity expansion, or margin improvement initiatives. The lack of institutional interest and stagnant promoter stake suggests limited confidence in the current business model. Without a defined strategy or visible catalysts, the stock remains speculative.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd